Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
Randa Bascharon, Founder, President and Orthopedic Surgeon at Sports Performance Institute of Las Vegas, shared a post on LinkedIn:
“Wharton’s Jelly is increasingly discussed in orthopedic and sports medicine settings, particularly among active patients looking for non-surgical options.
Wharton’s Jelly is derived from donated umbilical cord tissue and contains growth factors and signaling proteins that may support the body’s healing environment.
In clinical practice, it is considered in select cases involving tendon injuries, ligament issues, or certain joint conditions.
A few practical points are important:
- First, it is not the same as a steroid injection.
- Second, it is different from platelet-rich plasma.
- Third, it is not a universal substitute for surgery.
Candidacy varies.
The decision to consider a biologic injection depends on the diagnosis, severity of tissue damage, functional goals, prior treatments, and imaging findings.
Thoughtful patient selection matters.
For athletes and active adults, the real question is not whether a treatment is popular.
It is whether it aligns with the biology of their specific injury and their long-term performance goals.
If you are seeing more patients ask about biologics, how are you approaching education and expectation setting in your practice?
Educational only.
A diagnosis and treatment plan require an in-person evaluation.”

See more in the gallery.
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer